Vicken H Karageozian

6537545, Mar 25, 2003

Sep 7, 2000

09/656849

Hamper Karageozian - San Juan Capistrano CA
John Y. Park - Santa Ana CA
Vicken Karageozian - San Juan Capistrano CA
Phillip Baker - Walnut Creek CA
Anthony Nesburn - Malibu CA

ISTA Pharmaceuticals, Inc. - Irvine CA

A61K 3844

424 944, 424 942, 424 9462, 424429, 424427, 424 7804

An Enzyme Orthokeratology method is provided for correcting refractive errors in the eye of a subject mammal. Accelerating reshaping of the cornea is accomplished by administering a corneal hardening amount of a corneal hardening agent to the eye of the subject. Reformation is accomplished under the influence of a rigid contact lens or a series of lenses having a concave curvature that will correct a refractive error. The cornea rapidly reshapes its convex curvature to the concave curvature of the contact lens, rendering the eye emmetropic. The cornea is permitted to âhardenâ to retain the new emmetropic shape. After âhardeningâ has occurred, the lens rendering the eye emmetropic is removed.

6551590, Apr 22, 2003

Dec 2, 1999

09/453012

Hampar L. Karageozian - San Juan Capistrano CA
Vicken H. Karageozian - San Juan Capistrano CA
Maria Cristina Kenney - Malibu CA
Jose Luis Gutierrez Flores - Tijuana, MX
Gabriel Arturo Carpio Aragon - Tijuana, MX
Anthony B. Nesburn - Malibu CA

ISTA Pharmaceuticals, Inc. - Irvine CA

A61K 3846

424 9462, 424 941, 424 946, 424 9461, 514 2

The invention provide a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of a mammalian eye without producing toxicity to the eye, the method comprising contacting with the vitreous humor an amount of a solution which contains hyaluronidase to provide a dose of at least 1 International Unit of hyaluronidase, the hyaluronidase being in purified form possessing intravitreal hemorrhage-clearing activity and being free from impurities that produce toxicity to the eye.

6610292, Aug 26, 2003

Nov 19, 1999

09/444003

Hampar Karageozian - San Juan Capistrano CA
Vicken Karageozian - San Juan Capistrano CA
Maria C. Kenney - Malibu CA
Jose L. G. Flores - Colonia Leyva Aleman, MX
Gabriel Arturo Carpio Aragon - Col. Aviacion, MX
Anthony B. Nesburn - Malibu CA

ISTA Pharmaceuticals, Inc. - Irvine CA

A61K 3846

424 9462, 424 9461, 424 946, 424 941

An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to the retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.

6863886, Mar 8, 2005

Feb 21, 2003

10/371850

Hampar Karageozian - San Juan Capistrano CA, US
Vicken Karageozian - San Juan Capistrano CA, US
Maria C. Kenney - Malibu CA, US
Jose L. G. Flores - Colonia Leyva Aleman, MX
Gabriel Arturo Carpio Aragon - Col. Aviacion, MX
Anthony B. Nesburn - Malibu CA, US

Advanced Corneal Systems - Irvine CA

A61K038/43

424 9462, 424 941, 424 9461, 424 9463, 424 9464, 424 9467, 424601, 52612313, 514912

An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.

6939542, Sep 6, 2005

Feb 14, 2003

10/369372

Hampar L. Karageozian - San Juan Capistrano CA, US
Vicken H. Karageozian - San Juan Capistrano CA, US
Maria Cristina Kenney - Malibu CA, US
Jose Luis Gutierrez Flores - Tijuana, MX
Gabriel Arturo Carpio Aragon - Tijuana, MX
Anthony B. Nesburn - Malibu CA, US

Ista Pharmaceuticals, Inc. - Irvine CA

A61K038/46

424 9462, 424 941, 424 946, 424 9461, 514 2

A thimerosal-free hyaluronidase preparation wherein the preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,000 MW. Also disclosed is a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of the eye, said method comprising the step of contacting at least one hemorrhage-clearing enzyme (e. g. , a β-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase or protein kinase) with the vitreous humor in an amount which is effective to cause accelerated clearance of blood therefrom.

7977385, Jul 12, 2011

Mar 14, 2003

10/389226

Vicken H. Karageozian - Laguna Beach CA, US
David Castillejos - Chula Vista CA, US
John Park - Santa Ana CA, US
Gabriel Arthuro Carpio Aragon - Tijuana, MX
Jose Luis Gutierres Floress - Tijuana, MX

Numoda Biotechnologies, Inc. - Philadelphia PA

A61K 31/17

514588, 514912

Methods and preparations for treating disorders of the eye and/or causing dissolution of corneal proteoglycans and organized healing of corneal stroma, softening of the cornea for non-surgical refractive correction of eyesight, removing corneal haze and opacification, inhibiting fibroblasts and preventing corneal fibrosis and scar formation, treating pterigiums and treating corneal neovascularization as well as iris neovascularization. Preparations containing a) urea, b) urea derivatives (e. g. , hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e. g. , adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, guanidinium chloride, guanidinium salts, thymidine, thymitadine, uradine, uracil, cysteine), reduced thioctic acid, uric acid, calcium acetyl salicylate, ammonium sulfate, isopropyl alcohol, ethanol, polyethylene glycol, polypropylene glycol or other compound capable of causing nonenzymatic dissolution of the corneal protoeglycans or f) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.

20030175259, Sep 18, 2003

Dec 12, 2002

10/319010

Hamper Karageozian - San Juan Capistrano CA, US
John Park - Santa Ana CA, US
Vicken Karageozian - San Juan Capistrano CA, US
Phillip Baker - Walnut Creek CA, US
Anthony Nesburn - Malibu CA, US

A61K038/43

424/094100

An Enzyme Orthokeratology method is provided for correcting refractive errors in the eye of a subject mammal. Accelerating reshaping of the cornea is accomplished by administering a corneal hardening amount of a corneal hardening agent to the eye of the subject. Reformation is accomplished under the influence of a rigid contact lens or a series of lenses having a concave curvature that will correct a refractive error. The cornea rapidly reshapes its convex curvature to the concave curvature of the contact lens, rendering the eye emmetropic. The cornea is permitted to “harden” to retain the new emmetropic shape. After “hardening” has occurred, the lens rendering the eye emmetropic is removed.

20030199574, Oct 23, 2003

Feb 13, 2003

10/367614

Vicken Karageozian - Laguna Beach CA, US
David Castillejos - Chula Vista CA, US
John Park - Santa Ana CA, US

Vitreo-Retinal Technologies, Inc. - Irvine CA

A61K031/343
A61K031/17
A61K031/155

514/468000, 514/580000, 514/588000, 514/595000, 514/634000

Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.